Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$104.74 USD
+0.07 (0.07%)
Updated May 10, 2024 04:00 PM ET
After-Market: $104.80 +0.06 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$104.74 USD
+0.07 (0.07%)
Updated May 10, 2024 04:00 PM ET
After-Market: $104.80 +0.06 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.
Abbott Labs to Close St. Jude Acquisition Later this Week
by Zacks Equity Research
Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.
AbbVie's Humira and Imbruvica Drive Performance in 2016
by Zacks Equity Research
AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.
Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout
by Zacks Equity Research
Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).
Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs
by Zacks Equity Research
Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.
Q3 Earnings Continue, Housing and Permits Mixed
by Mark Vickery
Housing starts fell 9% but building permits rose 6.3%. We also see earnings results from Morgan Stanley, U.S. Bancorp, Abbott Labs, Halliburton and Seagate.
Q2 Earnings Season Coming Up Roses
by Mark Vickery
Morgan Stanley, Abbott Labs and Halliburton all beat earnings expectations before the opening bell today.
Bear of the Day: AbbVie (ABBV)
by Kevin Cook
Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus
Parade of Mixed Earnings
by Sheraz Mian
Stocks have made solid gains in recent sessions, pushing the S&P 500 index above the 2100 level.
Bear of the Day: Abbott Labs (ABT)
by Eric Dutram
This stock could infect your portfolio thanks to its sluggish outlook and crumbling earnings estimates.